In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Junichi MatsubaraInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA (USA).ORCID 0000-0003-0116-5133 Sanjay KoulCenter for Discovery and Innovation (CDI), Hackensack Meridian Health (HMH), Nutley, NJ (USA).ORCID 0000-0002-9605-4825 Luis E Valencia SalazarDepartment of Pathology and Cell Biology, Columbia University, New York, NY (USA).ORCID 0000-0002-5499-1394 Taichi IsobeInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA (USA).ORCID 0000-0001-5686-1940 Dalong QianInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA (USA).ORCID 0000-0002-6261-5188 Michael F ClarkeInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA (USA).ORCID 0000-0001-6889-4926 Debashis SahooDepartment of Computer Science and Engineering, University of California San Diego (UCSD), San Diego, CA (USA).ORCID 0000-0003-2329-8228 Piero DalerbaCenter for Discovery and Innovation (CDI), Hackensack Meridian Health (HMH), Nutley, NJ (USA).ORCID 0000-0002-8815-4981 Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0Mtherapeutic Targeting of CD47 on Human Leukemia and Other Cancer Stem CellsP01CA139490 · NCI · STANFORD UNIVERSITY · PI CLARKE, MICHAEL · 2009 to 2013
$8.7MText Mining for High-fidelity Curation and Discovery of Gene-drug-phenotype RelationshipsR01LM005652 · NLM · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2000 to 2018
$6.2MMolecular and Functional Characterization of Colon Tumor Cancer Stem Cells and StU54CA126524 · NCI · STANFORD UNIVERSITY · PI QUAKE, STEPHEN R · 2006 to 2010
$5.6MMacrophage Polarization in Response to Infections and InflammationR01AI155696 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, SAHOO, DEBASHIS · 2020 to 2024
$4.9MUndergraduate Summer Research Experiences Support for Combining systems biology and structural biology to find new therapeuticsR01GM102365 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO · 2012 to 2021
$3.0MSelf-Renewal of Normal and Leukemic Stem CellsR01CA100225 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CLARKE, MICHAEL · 2004 to 2015
$2.9MSummer Student Research on the Application of Boolean AnalysisR01GM138385 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SAHOO, DEBASHIS · 2020 to 2023
$2.0MDissecting cell composition and drug sensitivity in human adenoid cystic carcinomas (ACCs).R01DE028961 · NIDCR · HACKENSACK UNIVERSITY MEDICAL CENTER · PI DALERBA, PIERO D · 2019 to 2023
$1.9MComputational methods for characterizing sources of variability in drug responseR35GM153195 · NIGMS · STANFORD UNIVERSITY · PI RUSS BIAGIO ALTMAN · 2024 to 2026
$1.0MPrecision therapeutics of inflammatory bowel disease guided by Boolean logicUG3TR003355 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAS, SOUMITA, GHOSH, PRADIPTA · 2020 to 2022
$937kFDA HHS U01 FD004979NCATS NIH HHS UG3 TR003355NCATS NIH HHS UL1 TR001873NCI NIH HHS P01 CA139490NCI NIH HHS P30 CA013696NCI NIH HHS R00 CA151673NCI NIH HHS R01 CA100225NCI NIH HHS R01 CA104987NCI NIH HHS U54 CA126524NCRR NIH HHS S10 RR029338NIAID NIH HHS R01 AI155696NIDCR NIH HHS R01 DE028961NIGMS NIH HHS R01 GM102365NIGMS NIH HHS R01 GM138385NIGMS NIH HHS R35 GM153195NIH HHS S10 OD020056NLM NIH HHS R01 LM005652
6 · The paper itselfAbstract
Background: Methods: In this study, we used Results: Our analysis identified E2F4 and TFDP1, two core components of the DREAM transcriptional repression complex, as transcriptional modulators preferentially activated by Conclusions: Our data identified E2F4 and the DREAM repressor complex as critical regulators of human CRC resistance to
Indexed as
Biological Sciencescancer chemotherapycancer stem cellscolon cancerdrug resistanceE2F4irinotecanMedical Sciences
Identifiers
PMID39896677
PMCPMC11785039
What OpenQuestion holds
Textmetadata
Read underepoch 390